All In MedTech

FDA Clearance Tracker · P140004-S010

Superion® Indirect Decompression System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 16, 2018

Approved

Time to decision

365 days

Received Nov 16, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140004-S010
Device name
Superion® Indirect Decompression System
Applicant location
Valencia, CA
Received
Nov 16, 2017
Decided
Nov 16, 2018
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P140004

Device type

Device class
Class III

Every decision under product code NQO

FDA's approval statement

As written in FDA's record.

Approval for revised labeling which incorporates data from the completed Post-Approval Study.

Source documents

Other decisions for Boston Scientific Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.